CN103635088B - 米格拉他汀类(Migrastatins)和其用途 - Google Patents

米格拉他汀类(Migrastatins)和其用途 Download PDF

Info

Publication number
CN103635088B
CN103635088B CN201280027680.5A CN201280027680A CN103635088B CN 103635088 B CN103635088 B CN 103635088B CN 201280027680 A CN201280027680 A CN 201280027680A CN 103635088 B CN103635088 B CN 103635088B
Authority
CN
China
Prior art keywords
methyl
compound
hydrogen
group
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280027680.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103635088A (zh
Inventor
赛缪尔·J·丹尼斯海弗斯凯
琼·马萨格
曼纽尔·巴连特·柯尔特斯
索聚尔·奥斯卡松
马尔科姆·摩尔
尼古拉斯·勒孔特
澳亚西克·奥尔福里
杨广丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN103635088A publication Critical patent/CN103635088A/zh
Application granted granted Critical
Publication of CN103635088B publication Critical patent/CN103635088B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
CN201280027680.5A 2011-04-07 2012-04-06 米格拉他汀类(Migrastatins)和其用途 Expired - Fee Related CN103635088B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161473131P 2011-04-07 2011-04-07
US61/473,131 2011-04-07
US201161508275P 2011-07-15 2011-07-15
US61/508,275 2011-07-15
PCT/US2012/032642 WO2012139074A2 (en) 2011-04-07 2012-04-06 Migrastatins and uses thereof

Publications (2)

Publication Number Publication Date
CN103635088A CN103635088A (zh) 2014-03-12
CN103635088B true CN103635088B (zh) 2016-06-15

Family

ID=46969857

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280027680.5A Expired - Fee Related CN103635088B (zh) 2011-04-07 2012-04-06 米格拉他汀类(Migrastatins)和其用途

Country Status (7)

Country Link
US (2) US9303009B2 (enExample)
EP (1) EP2693879B1 (enExample)
JP (2) JP5975581B2 (enExample)
CN (1) CN103635088B (enExample)
AU (1) AU2012239977B9 (enExample)
CA (1) CA2832439C (enExample)
WO (1) WO2012139074A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5975581B2 (ja) 2011-04-07 2016-08-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ ミグラスタチンおよびその使用
US10285646B1 (en) * 2018-02-27 2019-05-14 CeriBell, Inc. Connection quality assessment for EEG electrode arrays
CA3110877A1 (en) 2018-08-27 2020-03-05 Spinogenix, Inc. Fascin binding compounds for spinogenesis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124662A1 (en) * 2004-05-25 2009-05-14 Danishefsky Samuel J Migrastatin analogs in the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037783A1 (en) 2003-03-28 2007-02-15 Xin-Yun Huang Migrastatin analogs and uses thereof
CA2520732C (en) 2003-03-28 2012-12-04 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
WO2005019181A1 (en) 2003-08-19 2005-03-03 Cornell Research Foundation, Inc. Migrastatin analog cell migration inhibitors
CA2582766C (en) * 2004-09-23 2014-07-22 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
CN101918036A (zh) 2007-11-21 2010-12-15 康奈尔大学 抑制肌成束蛋白的方法
JP5975581B2 (ja) 2011-04-07 2016-08-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ ミグラスタチンおよびその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124662A1 (en) * 2004-05-25 2009-05-14 Danishefsky Samuel J Migrastatin analogs in the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Rational design and characterization of a Rac GTPase-specific small molecule inhibitor;Yuan Gao等;《PNAS》;20040518;第101卷(第20期);7618–7623 *
Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice;Dandan Shan等;《PNAS》;20050308;第102卷(第10期);3772–3776 *

Also Published As

Publication number Publication date
US20140024705A1 (en) 2014-01-23
JP2014510157A (ja) 2014-04-24
US9546146B2 (en) 2017-01-17
WO2012139074A3 (en) 2012-12-13
EP2693879A2 (en) 2014-02-12
CN103635088A (zh) 2014-03-12
EP2693879B1 (en) 2019-01-23
US9303009B2 (en) 2016-04-05
WO2012139074A2 (en) 2012-10-11
US20160221984A1 (en) 2016-08-04
AU2012239977B2 (en) 2016-10-20
EP2693879A4 (en) 2014-10-08
JP5975581B2 (ja) 2016-08-23
JP2016155873A (ja) 2016-09-01
AU2012239977A1 (en) 2013-10-31
AU2012239977B9 (en) 2016-11-17
CA2832439A1 (en) 2012-10-11
CA2832439C (en) 2017-08-29

Similar Documents

Publication Publication Date Title
US11969425B2 (en) Inhibitor of indoleamine-2,3-dioxygenase (IDO)
US10202400B2 (en) Cortistatin analogues and syntheses thereof
US9611287B2 (en) Trioxacarcins and uses thereof
US9023848B2 (en) Small-molecules as therapeutics
US20060287520A1 (en) Synthesis of salinosporamide A and analogues thereof
CN103635088B (zh) 米格拉他汀类(Migrastatins)和其用途
US12071436B2 (en) Anti-parasitic compounds and uses thereof
US11919886B2 (en) 4,9-dioxo-4,9-dihydronaphtho[2,3-B]furan-3-carboxamide derivatives and uses thereof for treating proliferative diseases and infectious diseases
HK1194617B (en) Migrastatins and uses thereof
HK1194617A (en) Migrastatins and uses thereof
HK40000485A (en) Inhibitor of indoleamine-2,3-dioxygenase (ido)
WO2014085791A2 (en) Compositions and uses thereof for treating multiple myeloma
WO2008124571A2 (en) Anti-viral compounds, compositions and methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160615

Termination date: 20200406

CF01 Termination of patent right due to non-payment of annual fee